Moreover, CD8+ T cells co-expressing PD1 and CD38 (PD1+CD38hiCD8+ T cells) have been identified as a dysfunctional T cell subset that inversely correlates with the therapeutic responsiveness of anti-PD1 therapy in patients with metastatic melanoma (17). This evidence concerns the gene PDCD1 and metastatic melanoma.